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Abstract
Inflammation caused by chronic hepatitis B virus (HBV) infection is associated with the development of cirrhosis and
hepatocellular carcinoma; however, the mechanisms by which HBV infection induces inflammation and inflammatory
cytokine production remain largely unknown. We analyzed the gene expression patterns of lymphocytes from chronic HBV-
infected patients and found that the expression of ZFP36, an AU-rich element (ARE)-binding protein, was dramatically
reduced in CD4
+ and CD8
+ T lymphocytes from chronic HBV patients. ZFP36 expression was also reduced in CD14
+
monocytes and in total PBMCs from chronic HBV patients. To investigate the functional consequences of reduced ZFP36
expression, we knocked down ZFP36 in PBMCs from healthy donors using siRNA. siRNA-mediated silencing of ZFP36
resulted in dramatically increased expression of multiple inflammatory cytokines, most of which were also increased in the
plasma of chronic HBV patients. Furthermore, we found that IL-8 and RANTES induced ZFP36 downregulation, and this
effect was mediated through protein kinase C. Importantly, we found that HBsAg stimulated PBMCs to express IL-8 and
RANTES, resulting in decreased ZFP36 expression. Our results suggest that an inflammatory feedback loop involving HBsAg,
ZFP36, and inflammatory cytokines may play a critical role in the pathogenesis of chronic HBV and further indicate that
ZFP36 may be an important target for anti-inflammatory therapy during chronic HBV infection.
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Introduction
Hepatitis B virus (HBV) is a non-cytopathic enveloped virus that
consists of partially double-stranded DNA that encodes viral
envelope proteins, core antigen (HBcAg), viral DNA polymerase,
and the X protein. Approximately 350 million people are infected
with HBV worldwide. HBV is highly prevalent in Southeast Asia,
China, and Africa, where approximately 10% of the total
population are HBV carriers [1]. During HBV infection, innate
and adaptive immune cells are activated and produce various
cytokines. These cytokines function in viral clearance but also
induce both acute and chronic inflammation and cause liver tissue
damage and cirrhosis [2]. Importantly, the defective immunity to
HBV observed inchronic HBV patients maybe dueto dysregulated
expression of pro- and anti-inflammatory cytokines [3,4,5,6,7].
However, the molecular mechanisms underlying the cytokine
dysregulation in chronic HBV patients have not been determined.
Cytokine expression is subjected to regulation by adenosine/
uridine (AU)-rich elements (ARE) and ARE-binding proteins. The
AU-rich elements are key regulatory elements that control
cytokine expression by inducing the degradation of many cytokine
mRNAs [8,9]. A number of mRNAs, nearly 15% of the human
transcriptome, have an ARE in their 39-untranslated region (UTR)
[10,11]. These mRNAs encode cytokines, chemokines, growth
factors, and pro-inflammatory enzymes involved in inflammation
and immune responses. AREs can be divided into several classes
based on their sequences and modes of degradation [12]. ARE-
binding proteins such as ZFP36, KSRP, and HUR recognize ARE
mRNAs, affecting their stability and translation and controlling
their mRNA decay [13].
ZFP36, also known as tristetraprolin (TTP), Nup475, TIS11, or
G0S24, is a member of the zinc-finger family of proteins [14].
Many target cytokine and chemokine mRNAs for ZFP36 have
been identified, including TNF-a, GM-CSF, IFN-c, IL-2, IL-3,
COX-2, VEGF, IL-6, IL-8, IL-10, IL-12, and CXCL1
[15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31]. ZFP36 is
predominantly localized to the cytoplasm and binds to mRNAs
containing class II AREs [32,33]. Mice lacking the ZFP36 gene
suffer from severe chronic inflammation, demonstrating the
importance of ZFP36 as a negative regulator of inflammatory
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are regulated by the p38 mitogen activated protein kinase
(p38MAPK) signaling pathway [36]. p38MAPK can phosphory-
late serine residues in ZFP36, impairing its ability to destabilize its
target mRNAs.
In an analysis of differential gene expression, we found that
ZFP36 mRNA expression was significantly reduced in lympho-
cytes, monocytes, and total PBMCs from chronic HBV patients.
We also performed multiplex cytokine assays and found that
multiple inflammatory cytokines were increased in the plasma of
these HBV patients. The reduced expression of ZFP36 in total
PBMCs and T lymphocytes from chronic HBV patients may
contribute to the elevated levels of inflammatory cytokines in the
plasma of these patients. To determine the effect of reduced
ZFP36 expression, we performed siRNA-mediated silencing of
ZFP36 in PBMCs from healthy donors. Silencing of ZFP36
resulted in increased expression of multiple inflammatory
cytokines, most of which were also elevated in the plasma of
chronic HBV patients. Importantly, we have identified IL-8,
RANTES, and HBsAg as negative regulators of ZFP36 expression.
These results suggest that a feedback loop involving HBsAg, IL-8,
RANTES, and ZFP36 may both initiate and maintain the
inflammatory environment in chronic HBV patients.
Methods
Patients
A total of 29 chronic HBV patients (22 men and 7 women) were
recruited for this study. All patients were HBsAg- and anti-HBc-
positive and HCV- and HIV-negative. Fifteen of the HBV patients
(11 men and 4 women) were from YouAn Hospital (Beijing,
China), and 14 of them (11 men and 3 women) were from 302
Hospital (Beijing, China). A total of 19 healthy donors (13 men
and 6 women) were also recruited for this study. The
characteristics of the patients and healthy donors are listed in
Table 1. All human subjects provided informed written consent.
All of the studies were approved by the Institutional Ethics
Committees for Human Studies at YouAn Hospital and 302
Hospital.
PBMC isolation and transfection with siRNA
Fresh blood from HBV patients and healthy donors was diluted
with phosphate-buffered saline (PBS, Hyclone, Logan, Utah, USA)
containing 5% fetal calf serum (FBS, Invitrogen Gibco, Carlsbad,
California, USA). PBMCs were isolated using Ficoll-Paque
TM
PLUS (GE Healthcare, Buckinghamshire, England) and transfect-
ed using an AmaxaH Human T Cell NucleofectorH Kit (Lonza,
Cologne, Germany). The cells were cultured in 12-well plates
containing 2 ml RPMI 1640 medium (Hyclone) supplemented
with 10% FBS and 1–5 ng/ml human IL-7 (Biolegend, San
Diego, California, USA) in a humidified 37uC incubator in the
presence of 5% CO2 for 24 hours. Transfection was performed
using a NucleofectorH Device (Lonza) with program V-024.
The siRNA sequences used were as follows: ZFP36, 59-
CGACGAUAUAAUUAUUAUA-39 [36] and negative control,
59-CCUACGCCACCAAUUUCGU-39 (Bioneer, Daejeon, South
Korea).
Stimulation of PBMCs
Human PBMCs were cultured at 37uC in the presence of 5%
CO2 in RPMI 1640 medium supplemented with 10% FBS. Ninety
six-well plates (Costar Corning, Lowell, Massachusetts, USA) were
coated with 200 ml/well of PBS containing 1 mg/ml anti-CD3 and
anti-CD28 antibodies (eBioscience, San Diego, California, USA)
by incubating the plates overnight at 4uC or for 2–3 hours at
37uC/5% CO2. The PBMCs were then seeded at a density of 1–
1.5610
6 cells/ml and stimulated with anti-CD3/CD28 or soluble
CpG ODN2006 at a final concentration of 10 mg/ml (59-
TCGTCGTTTTGTCGTTTTGTCGTT-39, Invitrogen) for 1–
3 days.
To assess T cell activation, the expression of CD25 and CD69
on CD4
+ and CD8
+ T lymphocytes was measured 24 hours after
anti-CD3/CD28 stimulation. The PBMCs were suspended in a
volume of 1 ml, labeled with 1 ml CFSE (carboxyfluorescein
succinimidyl ester) 5 mM, (Sigma-Aldrich, St. Louis, Missouri,
USA), and stimulated. The proliferation of the cells was assessed
by examining the dilution of CFSE by flow cytometry. Apoptosis
was assessed by Annexin V staining, and cell cycle status was
determined by propidium iodide staining (Sigma). All results were
collected using a BD FACS Canto
TM II with corresponding
antibodies (BD, Franklin Lakes, New Jersey, USA).
Measurement of cytokine secretion
Plasma samples were collected from HBV patients and healthy
donors by centrifuging fresh blood at 400 g for 5 minutes. For
analysis of cytokine production by PBMCs, PBMCs were
stimulated for 3 days beginning 24 hours after transfection, and
supernatants were collected. All cytokines were measured by
Luminex 200 (Millipore, Billerica, Massachusetts, USA) using a
Bio-PlexTM Reagent Kit, Diluent Kit, and human Grp I
Cytokine 27-Plex Panel (Bio-Rad, Hercules, California, USA)
according to the manufacturer’s instructions.
In vitro treatment of PBMCs
Freshly isolated PBMCs from healthy donors were cultured with
recombinant HBsAg purified from prokaryotic expression and
kindly provided by the Academy of Military Medical Sciences,
Beijing, China at a final concentration of 2 mg/ml. Cytokines
(PeproTech, Rocky Hill, New Jersey, USA) were added to cell
cultures at concentrations equivalent to the mean concentrations
found in the plasma of HBV patients (IL-8: 40 pg/ml, RANTES:
30 ng/ml, and IFN-c: 1 ng/ml). To assess the roles of various
signaling pathways, PBMCs were plated at densities of 1–1.5610
6
cells/ml in 96-well plates and cultured for 20 hours in the presence
of the following signaling inhibitors: SB203580, 40 mM (Sigma-
Aldrich); H89-Dihydrochloride, 20 pM (Merck, Darmstadt, Ger-
many); and Bisindolylmaleimide I, 20 nM (Merck). After treat-
ment, PBMCs were collected and prepared for RNA extraction
and real-time PCR analysis.
Table 1. Characteristics of CHB patients and healthy donors.
Characteristic Value
HBV patients Healthy donors
Number 29 19
% Men 75.9 68.4
Age 35.9 (20–65) 39.5 (26–51)
HBV DNA 2.5610
7 (,500-2.0610
8)-
ALT level (U/L) 180.9 (17.9–1223) 16.7 (8.6–45.7)
AST level (U/L) 125.1 (12.6–902) 41.7 (11.8–81.9)
TBIL level (mmol/L) 57.7 (4.7–425.1) 10.4 (6.1–21.2)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBIL, direct
bilirubin; TBIL, total bilirubin.
doi:10.1371/journal.pone.0033356.t001
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Total RNA was isolated from PBMCs using an RNAqueousH-
Micro Kit (Ambion, Austin, Texas, USA) and used in reverse
transcription PCR (RT-PCR) reactions using SuperscriptH III
First-strand Synthesis System for RT-PCR (Invitrogen, Carlsbad,
California, USA). Real-time PCR was carried out with an ABI
7900HT instrument (Applied Biosystems, Foster City, California,
USA) using SYBR Green Master Mix 26(ABI) in a 20 ml reaction
volume containing 0.2 ml of cDNA and 0.5 ml each of forward and
reverse real-time PCR primers (10 mM). The PCR conditions
were as follows: 1 cycle of 50uC for 2 min; 1 cycle of 95uC for
10 min; 40 cycles of 95uC for 15 s and 60uC for 1 min; and 1 cycle
of 95uC for 15 s, 60uC for 20 s, and 95uC for 15 s to analyze the
dissociation (melt) curves and determine the primer specificity. All
data were normalized to the level of the 18s rRNA transcript.
Primers were as follows: human 18s rRNA forward, 59-TCAAC-
TTTCGATGGTAGTCGCCGT-39 and reverse, 39-TCCTTG-
GATGTGGTAGC CGTTTCT-59; ZFP36 forward, 59-CATGG-
CCAACCGTTACACC-39 and reverse, 39-AGCGACAGGAGG-
CTCTCGTAC-59; IL-8 forward, 59-CTGGCCGTGGCTCT-
CTTG-39 and reverse, 39-CCTTGGCAAAACTGCACCTT-59;
RANTES forward, 59-GACACCACACCCTGCTGCT-39 and
reverse, 39-TACTCCTTGATGTGGGCACG-59; IFN-c forward,
59-CCAACGCAAAGCAATACATGA-39 and reverse, 39-CGC-
TTCCCTGTTTTAGCTGC-59 [37].
Statistical analysis
All data are presented as the means 6 SE. Data were analyzed
using GraghPad Prism 5.00 software, and data with p-
values,0.05 (t-test) were considered statistically significant.
Results
ZFP36 gene expression is downregulated in PBMCs of
HBV patients
Although it is known that inflammation during chronic HBV
infection is associated with liver pathogenesis and hepatocellular
carcinoma development [38], the critical regulators of chronic
inflammation during HBV infection have yet to be determined.
We first performed an analysis of differential gene expression in
CD8
+ T cells from chronic HBV (CHB) patients and healthy
donors (HD). As shown in Table S1, 527 genes displayed
significantly different levels of expression in T cells from CHB
than in those from HD (p,0.01). Our initial analysis found that
ZFP36 mRNA expression in CD8
+ T lymphocytes from CHB
patients was reduced by 70% (p=0.0006; n=5) when compared
to that in healthy donors. In contrast, the expression of two other
members of the ZFP36 family, ZFP36L1 and ZFP36L2, was not
changed (data not shown). We further confirmed this finding in
CD4
+ T lymphocytes (Figure 1A) (p=0.0005), CD8
+ T lympho-
cytes (Figure 1B) (p=0.0045), CD14
+ monocytes (Figure 1C)
(p=0.0071), and total PBMCs (Figure 1D) (p=0.0029) from
additional CHB patients (n=13) and HD (n=9) by qPCR. These
results demonstrate that ZFP36 gene expression is markedly
downregulated in multiple leukocyte populations and in total
PBMCs from chronic HBV patients.
The clinical characteristics of all the patients and healthy donors
enrolled in the study are listed in Table 1. The age and sex of the
two populations were largely comparable. Interestingly, we found
a significant negative correlation between ZFP36 expression in
PBMCs and ALT levels in HBV patients (r=20.675, R
2=0.456,
and p=0.011) (Figure 1E). ZFP36 expression was weakly inversely
correlated with AST levels (p=0.056), and no correlations were
found between ZFP36 expression and HBV DNA amount
(p=0.416) or TBIL level (p=0.770) (Figure 1F). Given the known
roles of ZFP36 in regulating cytokine production, these results
suggest that the reduced expression of ZFP36 in the PBMCs of
CHB patients may play a role in the chronic inflammation
observed in these patients.
Expression of cytokines in the plasma of CHB patients
ZFP36 regulates cytokine expression by binding to AU-rich
element sequences to destabilize cytokine mRNA. We thus
hypothesized that the downregulation of ZFP36 in PBMCs of
CHB patients contributed to an increased expression of inflam-
matory cytokines in chronic HBV patients. We first measured the
plasma levels of 25 different cytokines. The expression of IL-1b,
IL-1RA, IL-2, IL-8, IL-13, TNF-a, EOTAXIN, RANTES,
VEGF, and IP10 in CHB patients (n=16) was significantly higher
than that in healthy donors (n=10) (p,0.05) (Figure 2A). The
differences in the expression levels of IL-7, IFN-c, MCP1, and
MIP1a (p,0.01) and of IL-4 and IL-12 (p,0.001) were even more
pronounced (Figure 2A). Moreover, we observed a tendency
toward increased levels of plasma GM-CSF, MIP1b, IL-5, IL-6,
IL-9, IL-10, IL-15, IL-17, and PDGF-bb in CHB patients;
however, these differences were not statistically significant
(p.0.05) (Figure 2B). Despite the elevated levels observed for
many cytokines in the plasma of CHB patients, microarray data
showed that the mRNA levels of these cytokines were similar in T
lymphocytes from CHB patients and healthy donors (data not
shown). This finding suggests that the mRNA transcripts of these
cytokines in T lymphocytes were not affected and that the elevated
cytokine protein levels observed in CHB patients were due to post-
transcriptional mechanisms.
Interestingly, we found a strong correlation between IL-8 and
ALT levels (r=0.611, R
2=0.373, and p=0.012) and between IL-
8 and AST levels in CHB patients (r=0.507, R
2=0.258, and
p=0.045) (Figure 2C). Furthermore, we detected strong correla-
tions between IL-1RA and HBV DNA levels (r=0.559,
R
2=0.313, and p=0.024) and between TNFa and HBV DNA
levels (r=0.788, R
2=0.620, and p=0.0003) (Figure 2C). These
results suggest that inflammatory cytokines may directly influence
liver pathology and that the levels of these cytokines may be
correlated with HBV viral loads.
Effect of silencing ZFP36 in PBMCs on cytokine
production
Although studies in the ZFP36-deficient mouse model have
clearly demonstrated that ZFP36 negatively regulates inflamma-
tory cytokine production [34,39], the function of ZFP36 in
primary human T lymphocytes is not clear. To directly assess the
effect of reduced ZFP36 expression on cytokine production by
primary human lymphocytes, we knocked down ZFP36 expression
in PBMCs using RNAi. PBMCs from healthy donors were
transfected by nucleofection with ZFP36-specific siRNA or control
siRNA and then cultured for 48 hours. ZFP36-specific siRNA
decreased ZFP36 mRNA expression by .75% in PBMCs from
different donors (Figure 3A). Furthermore, we failed to detect
ZFP36 protein expression in both wildtype and siRNA-treated
PBMCs even when 5610
6 cells were used for Western blots,
suggesting a low level of ZFP36 protein expression. The siRNA-
treated human PBMCs were stimulated with anti-CD3/anti-
CD28 or soluble CpG ODN2006 for 3 days, and cytokine
production was analyzed. In contrast to the results of experiments
performed on inbred mice, we observed large donor-to-donor
variations in the production of cytokines by activated T
lymphocytes and monocytes (Figure 3B, 3C). Silencing ZFP36 in
PBMCs resulted in significantly enhanced production of TNF-a,
Regulation of Inflammation by ZFP36 during HBV
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IFN-c, and VEGF following anti-CD3/CD28 stimulation
(Figure 3B) and of TNF-a, IL-1b, IL-1RA, IL-5, GM-CSF,
MIP1a, MIP1b, IL-15, IL-9, IFN-c, and RANTES following CpG
ODN2006 stimulation (Figure 3C).
We next addressed the possibility that the increased cytokine
production in ZFP36 siRNA-treated T lymphocytes and mono-
cytes was an indirect effect of the ability of ZFP36 to regulate cell
activation, proliferation, or survival [13]. We examined whether
siRNA-mediated silencing of ZFP36 in T lymphocytes affected T
cell activation, proliferation, or survival. As shown in Figure 4,
silencing ZFP36 in T lymphocytes had no apparent effect on their
activation, proliferation, cell cycle progression, or apoptosis. These
results suggest that ZFP36 specifically regulates cytokine produc-
tion in primary human T lymphocytes.
The plasma cytokine profiles of CHB patients (Figure 2) and the
supernatant cytokine profiles of ZFP36 siRNA-treated PBMCs
stimulated with either anti-CD3/CD28 or CpG ODN2006 are
compared in Table 2. Out of the 25 cytokines that were
upregulated either in the plasma of CHB patients or in the
supernatant of ZFP36 siRNA-treated PBMCs stimulated with
anti-CD3/CD28 or CpG ODN2006, seven of them were shared
between patient plasma and the supernatant of ZFP36 siRNA-
treated PBMCs stimulated with anti-CD3/CD28: TNF-a, IFN-c,
MCP1, VEGF, IL-1b, IL-4, and IL-13. In addition, six cytokines
were upregulated in both patient plasma and the supernatant of
ZFP36 siRNA-treated PBMCs stimulated with CpG2006: TNF-a,
IFN-b, MIP1a, RANTES, IL-1b, and IL-1RA. Among these
elevated cytokines, TNF-a, IFN-c, and IL-1b were upregulated in
ZFP36 siRNA-treated PBMCs stimulated with either anti-CD3/
Figure 1. Downregulation of ZFP36 in T lymphocytes, monocytes, and total PBMCs of chronic HBV patients. ZFP36 mRNA expression
was measured by qPCR in purified CD4
+ T lymphocytes (A), CD8
+ T lymphocytes (B), CD14
+ monocytes (C), and total PBMCs (D) from chronic HBV
patients (n=13) and healthy donors (n=9). ZFP36 expression in control cells was defined as 1.0. P values for all four groups were ,0.01. E. Inverse
correlation between ZFP36 expression in total PBMCs and ALT level (U/L) in chronic HBV patients (p=0.011). F. Correlation between ZFP36
expression in total PBMCs and HBV DNA (p=0.416), AST level (p=0.056), and TBIL level (p=0.770) in chronic HBV patients.
doi:10.1371/journal.pone.0033356.g001
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expression of these inflammatory cytokines in both T cells and
monocytes. Furthermore, the ability of ZFP36 to modulate the
expression of diverse cytokines in both T cells and monocytes
suggests that reduced levels of ZFP36 may also result in enhanced
cytokine production in other cell types.
HBsAg, IL-8, RANTES, and IFN-c induce the
downregulation of ZFP36 in PBMCs
The downregulation of ZFP36 expression in PBMCs of CHB
patients may be mediated by HBV viral components and/or
cytokines. To determine the factors that can induce ZFP36
downregulation, we tested the effects of various cytokines and
Figure 2. Plasma cytokine profiles of chronic HBV patients. A and B. Luminex results show the expression levels of 25 cytokines in the
plasma of healthy donors (HD) (n=10) and chronic HBV patients (n=16). The expression levels (pg/ml) of cytokines that displayed significant
differences between healthy donors and HBV patients are shown in A, and the expression levels of cytokines that did not display significant
differences are shown in B. * p,0.05; ** p,0.01; *** p,0.001. C. Correlation between IL-8 and ALT levels (p,0.05); IL-8 and AST levels (p,0.05); TNF-
a and HBV DNA levels (p,0.001); and IL-1RA and HBV DNA levels (p,0.05) in chronic HBV patients.
doi:10.1371/journal.pone.0033356.g002
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healthy donors were cultured for 20 hours with 2 mg/ml HBsAg
or with concentrations of cytokines equivalent to those found in
the plasma of CHB patients. ZFP36 mRNA expression was
significantly reduced in total PBMCs upon co-culture with HBsAg
(p=0.0001), IL-8 (p=0.015), RANTES (p=0.035), or IFN-c
(p=0.037) (Figure 5A). This effect was specific, as 12 other
cytokines that were elevated in CHB patients (TNF-a, IL-1b, IL-2,
IL-17, IL-7, IL-12, IL-4, MIP1a, IP10, IL-13, EOTAXIN, and
VEGF) did not affect ZFP36 expression (data not show).
To address the possibility that HBsAg may induce ZFP36
downregulation indirectly by inducing cytokine production, we
analyzed IL-8, RANTES, and IFN-c gene expression in HBsAg-
stimulated PBMCs by qPCR. Indeed, HBsAg treatment of total
PBMCs resulted in increased expression of IL-8 (p=0.022) and
RANTES (p=0.025) but not of IFN-c (p=0.648) (Figure 5B).
These data suggest that the presence of HBsAg during chronic
HBV infection in vivo may enhance IL-8 and RANTES expression,
resulting in the downregulation of ZFP36 expression and the
upregulation of inflammatory cytokine production. Importantly,
Figure 3. Effect of siRNA-mediated silencing of ZFP36 on cytokine production by T cells. A. Extent of ZFP36 silencing in PBMCs from
healthy donors (n=4). Total PBMCs from healthy donors were transfected by nucleofection with non-specific siRNA (NC siRNA) or ZFP36-specific
siRNA (ZFP36 siRNA). qPCR analysis was used to quantify the expression of ZFP36 (p,0.001). B. Cytokine profiles in the supernatant of transfected
and stimulated (anti-CD3/CD28) PBMCs. C. Cytokine profiles in the supernatant of transfected and stimulated (CpG ODN2006) PBMCs. The expression
levels (pg/ml) of cytokines that displayed significant in control and ZFP36-silenced PBMCs are shown. * p,0.05; ** p,0.01; *** p,0.001. Data were
obtained using cells from 4 different donors.
doi:10.1371/journal.pone.0033356.g003
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enhanced RANTES production (Figure 3C), suggesting a feedback
loop.
IL-8-induced downregulation of ZFP36 in PBMCs can be
blocked by bisindolylmaleimide I
IL-8 and RANTES are chemotactic for many cell types,
including T lymphocytes, eosinophils, and basophils, and have
many receptors. The most frequently studied receptors are the G
protein-coupled serpentine receptors CXCR1 and CXCR2, which
can induce signaling through a PKC-dependent pathway [40]. To
better understand the mechanisms by which ZFP36 is downreg-
ulated during chronic HBV infection, we next studied the
pathways that IL-8 uses to mediate its downregulation of ZFP36
expression.
PBMCs were cultured with IL-8 with or without pre-incubation
with signaling pathway inhibitors including bisindolylmaleimide I
(inhibitor of PKC signaling pathway), SB 203580 (inhibitor of
P38MAPK), and H-89 dihydrochloride (inhibitor of PKA). ZFP36
expression was measured by qPCR. As expected, the expression of
ZFP36 mRNA in PBMCs was reduced after incubation with IL-8
(p=0.004). This IL-8-induced reduction in ZFP36 mRNA
expression was inhibited by bisindolylmaleimide I treatment
(Figure 5C). Importantly, two other inhibitors, H-89 dihydrochlo-
ride and SB 203580, did not significantly affect IL-8-induced
downregulation of ZFP36. In addition, PBMCs incubated with
Figure 4. Effect of siRNA-mediated silencing of ZFP36 on T cell activation, proliferation, and survival. PBMCs from healthy donors were
transfected by nucleofection with non-specific siRNA (NC siRNA) or ZFP36-specific siRNA (ZFP36 siRNA). A. Expression of CD25 and CD69 in CD4
+ and
CD8
+ T cells was measured 24 h after stimulation with anti-CD3/CD28. Dotted lines: un-stimulated cells; solid lines: stimulated cells; grey lines: NC
siRNA-transfected cells; black lines: ZFP36 siRNA-transfected cells. B. CFSE dilution of labeled CD4
+ and CD8
+ T lymphocytes. Dotted lines: cells
transfected with NC siRNA; solid lines: cells transfected with ZFP36 siRNA. C. Cell cycle status of ZFP36 siRNA-transfected T cells. Cells were stained
with PI. Solid lines: cells transfected with NC siRNA; dotted lines: cells transfected with ZFP36 siRNA. D. Apoptotic rates of ZFP36 siRNA-transfected T
cells as determined by Annexin V staining. Percentages represent the frequency of Annexin V
+ cells within the CD4
+ and CD8
+ T cell populations of
PBMCs transfected with NC siRNA or ZFP36 siRNA.
doi:10.1371/journal.pone.0033356.g004
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levels similar to those observed in untreated PBMCs, demonstrat-
ing that bisindolylmaleimide I alone does not affect ZFP36
expression (p=0.217). Together, these results suggest that IL-8-
mediated downregulation of ZFP36 in PBMCs likely occurs
through the PKC signaling pathway.
Discussion
A significant fraction of CHB patients develop liver cirrhosis
and hepatocellular carcinoma, and the dysregulated expression of
pro- and anti-inflammatory cytokines during the course of the
disease may contribute to the pathogenesis of CHB
[3,4,5,6,38,41]. To develop an effective therapeutic strategy for
CHB, it is essential to understand the molecular mechanisms
underlying the dysregulated expression of pro- and anti-inflam-
matory cytokines in CHB patients. To achieve this goal, we have
performed a differential gene expression analysis in lymphocytes
from CHB patients and found that ZFP36 expression was
decreased. Given the known roles of ZFP36 in regulating cytokine
production in animal models and cell lines, we have further
analyzed its function in primary human lymphocytes.
Our studies have resulted in several important findings. First, the
expression of ZFP36, a key regulator of cytokine production, is
reduced not only in CD4
+ and CD8
+ T lymphocytes, but also in
CD14
+ monocytes from CHB patients. Furthermore, total PBMCs
also displayed significantly reduced ZFP36 mRNA expression,
indicating an overall reduction of ZFP36 expression in hematopoi-
etic cells. This is the first observation linking dysregulated ZFP36
expression with CHB infection. Second, ZFP36 expression is
strongly inversely correlated with serum ALT levels and weakly
inversely correlated with AST levels in CHB patients. These results
are consistent with mouse genetic studies showing that ZFP36
negatively regulates the production of inflammatory cytokines
including TNF-a, IL-1b, and IL-6 [34,39]. Third, we have
performed systemic cytokine expression profiling of plasma cytokine
levels from CHB patients. Strikingly, our results indicate that out of
the 25 analyzed cytokines, sixteen cytokines/chemokines/growth
factors were significantly upregulated, and not a single cytokine was
expressed at lower levels in the CHB patients than in healthy
donors, indicating a general chronic activation of immune cells
during CHB infection. Fourth, our RNAi experiments demonstrate
that ZFP36 regulates a wide array of cytokines in PBMCs, and this
Table 2. Comparison of cytokines increased in the plasma of CHB patients and the supernatant of PBMCs transfected with ZFP36
siRNA and stimulated with anti-CD3/CD28 or CpG.
Plasma Supernatant ARE Target of ZFP36
Anti-CD3/CD28 CpG 2006
TNF-a * * ** Yes Yes [15,16]
IFN-a ˜ ** *** * Yes Yes [18,19]
GM-CSF ** ** Yes Yes [17]
MCP1 ** ** Yes Yes [19,48]
MIP1a ** ** Not determined -
MIP1b * Not determined -
EOTAXIN * Yes Not determined
RANTES * *** Not determined -
VEGF * *** Yes Yes [24]
IP10 * Yes Not determined
PDGF-bb Yes Not determined
IL-1b * * * Yes Yes [36]
IL-1RA * ** Not determined -
IL-2 * Yes Yes [20]
IL-4 *** ** Yes HuR Target [49,50]
IL-5 * Yes Not determined
IL-6 ** Yes Yes [25,26]
IL-7 ** Yes Not determined
IL-8 * Yes Yes [27]
IL-9 ** * Not determined -
IL-10 ** Yes Yes [28,29]
IL-12 *** Yes Yes [30]
IL-13 * ** Yes HuR Target [51]
IL-15 * Yes Not determined
IL-17 * Yes ZFP36-like
*p,0.05;
**p,0.01;
***p,0.001.
ARE data were obtained from the ARE-Containing mRNA Database from http://brp.kfshrc.edu.sa/ARED/. Bracketed numbers indicate references.
doi:10.1371/journal.pone.0033356.t002
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survival. Fifth, we have identified a feedback pathway involving
HBsAg and IL-8 that mediates the downregulation of ZFP36
expression in PBMCs. Together, these results have provided
important insight into the mechanisms controlling the dysregulated
pro-inflammatory cytokine production in CHB patients.
Interestingly, we have observed not only a strong inverse
correlation between the ALT levels and ZFP36 expression levels in
CHB patients (Figure 1E), but also a strong positive correlation
between the patients’ ALT levels and plasma IL-8 levels
(Figure 2C). Importantly, IL-8 is a potent inducer of ZFP36
downregulation (Figure 5A). These results are consistent with the
Figure 5. Reduced expression of ZFP36 in PBMCs after treatment with HBsAg, IL-8, RANTES, or IFN-c.A .ZFP36 expression in PBMCs
cultured with HBsAg (2 mg/ml), IL-8 (40 pg/ml), RANTES (30 ng/ml), or IFN-c (1 ng/ml) for 20 hours. Shown are ZFP36 mRNA expression levels of
samples from six healthy donors as measured by qPCR. B. Increased production of IL-8 and RANTES but not IFN-c by HBsAg-stimulated PBMCs.
PBMCs were cultured and tested as in A. C. Effect of bisindolylmaleimide I on IL-8-induced ZFP36 downregulation in PBMCs. PBMCs were cultured
with IL-8 as in A in the presence of PKC inhibitor (BIS), PKA inhibitor (H89), or p38MAPK inhibitor (SB 203580). The expression of ZFP36 was measured
by qPCR. *p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0033356.g005
Regulation of Inflammation by ZFP36 during HBV
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33356notion that inflammatory cytokines such as IL-8 induce liver
damage and promote further inflammation. In contrast, AST
levels and ZFP36 expression levels were only weakly correlated,
suggesting that AST and ALT levels may be regulated by different
mechanisms in CHB patients.
Our results suggest that the reduced expression of ZFP36 in
multiple cell types in CHB patients contributes to the elevated
levels of inflammatory cytokines observed in these patients.
Experiments in which ZFP36-silenced T lymphocytes or mono-
cytes were stimulated with anti-CD3/CD28 or with CpG,
respectively, clearly demonstrate that silencing of ZFP36 pro-
foundly impacts cytokine production capacity in these cells. Of 25
cytokines tested, 12 were significantly elevated in T cells, and 11
were significantly elevated in monocytes. A comparison of the
cytokines that were elevated in the plasma of CHB patients and
those that were elevated in the supernatants of ZFP36 siRNA-
treated PBMCs stimulated with anti-CD3/CD28 revealed that
seven were shared: TNF-a, IFN-c, MCP1, VEGF, IL-1b, IL-4,
and IL-13 (Table 2). All seven of these cytokines have identified
AREs and are established targets of ZFP36 or the AU-rich-binding
protein HuR, suggesting a critical role for AU-rich RNA-binding
proteins in regulating inflammation during CHB infection.
Furthermore, a comparison of the cytokines that were elevated
in the plasma of CHB patients and those that were elevated in the
supernatants of ZFP36 siRNA-treated PBMCs stimulated with
CpG revealed that six were shared: TNF-a, IFN-c, MIP1a,
RANTES, IL-1b, and IL-1RA. The levels of several other
cytokines, including EOTAXIN, IP10, IL-2, IL-7, IL-8, and IL-
12, were only elevated in the plasma of CHB patients but not in
anti-CD3/CD28- or CpG-stimulated supernatants. This is likely
due to the production of these cytokines by other types of cells, as
the supernatants contained cytokines only from anti-CD3/CD28-
simulated T lymphocytes or CpG-stimulated monocytes. Con-
versely, the levels of several cytokines were increased in the
supernatants of ZFP36 siRNA-treated PBMCs stimulated with
anti-CD3/CD28 (GM-CSF, IL-5, IL-9, IL-10, and IL-17) or with
CpG (GM-CSF, MIP1b, IL-6, IL-9, and IL-15) but not in the
plasma of CHB patients, suggesting that the production of these
cytokines may be subjected to additional layers of regulation
during CHB infection.
We next addressed the mechanism by which ZFP36 expression
is reduced in the PBMCs of CHB patients by testing the effects of
HBsAg and 15 cytokines that were elevated in CHB patient
plasma on ZFP36 expression in total PBMCs from healthy donors.
Our results indicate that HBsAg, IFNc, IL-8, and RANTES
significantly downregulated the expression of ZFP36. Further-
more, we found that HBsAg induced the expression of both IL-8
and RANTES in PBMCs. This observation is consistent with a
very recent report showing that HBV induces IL-8 by directly
activating its transcription [42]. The role of IL-8 in HBV
pathogenesis has been well documented. The X protein of HBV
activates IL-8 gene expression through NF-kB and C/EBP-like
cis-elements [43,44]. Furthermore, the significantly elevated IL-8
levels detected in CHB patients are associated with hepatic flares
and liver damage [5,45]. Our results suggest that one mechanism
of IL-8-mediated liver damage is mediated through the downreg-
ulation of ZFP36 expression, which in turn causes the release of
more inflammatory cytokines. This feedback loop likely helps to
maintain the inflammatory environment during HBV infection.
Importantly, our data indicate that RANTES is a target of ZFP36
suppression in monocytes and it is also a potent inducer of ZFP36
downregulation in PBMCs, suggesting a RANTES/ZFP36
feedback amplification of inflammation.
IFN-c and TNF-a are hallmarks of the activation of HBV-
specific CTLs, and both cytokines play major roles in the
noncytolytic clearance of HBV infection in the liver [46]. ZFP36
downregulation in the PBMCs of CHB patients may lead to the
upregulation of these two cytokines. It is puzzling that increased
levels of TNF-a are associated with higher levels of HBV viremia.
These results suggest that the enhanced levels of TNF-a and/or
IFN-c may play a detrimental role in the induction of liver
damage. This is consistent with a report showing that elevated
levels of inflammatory cytokines such as IL-8 and IFN-a are
correlated with higher HBV viral loads and increased liver
damage [5]. Although many of the cytokines that are elevated in
CHB patients have been reported to display anti-viral activity,
they failed to drive viral clearance in CHB patients. It is thus likely
that viral clearance depends on a full restoration of exhausted T
lymphocytes [47].
In summary, our studies suggest that ZFP36 is a key regulator of
inflammation during CHB infection. HBV viral components such
as HBsAg and the X protein upregulate IL-8 and other cytokines,
including RANTES, to downregulate ZFP36 expression, which
results in a de-repression of many inflammatory cytokines,
including RANTES. To develop an effective therapy, this vicious
inflammatory loop must be disrupted. Given its broad roles in
controlling inflammatory cytokine production, ZFP36 may
therefore prove to be an ideal therapeutic target. Future studies
examining the link between dysregulated expression of ZFP36 and
liver cirrhosis and hepatocellular carcinoma will thus provide
critical information regarding the therapeutic value of targeting
ZFP36 in chronic HBV infection.
Supporting Information
Table S1 Human CD8
+ T cells were purified using positive
selection beads from three healthy donors and three chronic HBV
patients. The purity was higher than 90% as assessed by flow
cytometric analysis. Total RNA was extracted using mirVana kit.
Total RNA (200 ng) was used for microarray hybridization.
Differential gene expression was analyzed using one-way
ANOVA. Genes that showed dramatically changed (fold
change.2.0, p,0.05) were shown in the table.
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